n dopamine agonist patient share first line. Patients will
benefit from the introduction of new agents, including new formulations and
line extensions within the dopamine agonist class. However,
GlaxoSmithKline's Requip will face generic competition in 2008, so the
overall market for dopamine agonists will begin to diminish, despite the
launch of new agents in this class."
About Treatment Algorithm Insight Series
Decision Resources combines in-depth primary research with the most
extensive claims-based longitudinal patient-level data from PharMetrics(R)
to provide exceptional insight into physicians' prescribing trends and the
factors that drive therapy product choice, from diagnosis through multiple
courses of treatment, for a specific disease.
For each disease examined, Decision Resources' Treatment Algorithms
Insight Series provides:
-- Summary of U.S. medical practice based on interviews with leading
experts in the field
-- Qualitative diagnosis/referral/treatment algorithm for the
United States
-- Drug usage by lines of therapy (1st, 2nd, 3rd line)
-- Discussion of key freeform combinations by lines of therapy
-- Product share (class and specific compound level) within each line of
therapy (1st, 2nd, 3rd line)
-- Progression of therapy from key 1st line products
-- Pathway to key therapies from previous therapies
-- Qualitative analysis of 2-year forecast incorporating upcoming
launches, changes in reimbursement, etc.
About Decision Resources
Decision Resources, Inc., (http://www.DecisionResources.com) is a world leader
in healthcare market research publications, advisory services, and
consulting designed to help clients shape strategy, allocate resources, and
master their chosen markets.
All company, brand, or product names contained in this document may be
trademarks or registered
'/>"/>
SOURCE Decision Resources
 Copyright©2007 PR Newswire. | |
Page: 1 2 3 Related medicine technology :1.
Clinical Data Suggest Decreased Bleeding Risk in People With Severe
Hemophilia A While Maintaining Factor VIII Levels Above One Percent2.
Velcade (Bortezomib) for Injection Based Therapies Produced
Complete Remission Rates as High as 54 Percent in Patients With
Previously Treated Multiple Myeloma3.
Velcade (bortezomib) for Injection Based Therapies Achieved
Survival Rates as High as 100 Percent in Newly Diagnosed Multiple
Myeloma Patients4.
Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides
Sustained Immune Response in 100 Percent of Women up to 55 Years of
Age5.
Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free
Survival by 45 Percent in Patients With Intermediate-Risk Kidney
Cancer6.
Data Published in The Lancet Show Gardasil was 100 Percent
Effective in Preventing High-Grade Vulvar and Vaginal Lesions
Caused by HPV Types 16 and 187.
Waismann Method Survey Reveals 65 Percent of Women Seeking Opiate
Dependency Treatment Are Mothers8.
Eighty-one Percent of U.S. Adults say that Birth Control Pills and
Procedures Should Be Covered by Health Insurance9.
Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100
Percent Protection Against Precancerous Lesions Caused By
Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than
Five Years10.
Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus
Docetaxel Reduces Growth of Both Hormone-Dependent and
Hormone-Independent Prostate Cancer by Up to 94 Percent in
Preclinical Studies11.
Newly Published Data from Large Study Support Cardiovascular Safety
of Avandia (Rosiglitazone Maleate)